102) All three patients responded to treatment. |
103) into domestic sewage network without any treatment. |
104) nd 35% of US-born patients completed LTBI treatment. |
105) lipid was significantly elevated post Al treatment. |
106) llected 7 and 14 days after initiation of treatment. |
107) she was admitted to hospital for surgical treatment. |
108) the liver tissue did not increase in any treatment. |
109) w strategies for prevention and antiviral treatment. |
110) ot predict outcomes during either half of treatment. |
111) ased vascular proliferation following APC treatment. |
112) l control) includes rats that received no treatment. |
113) ffered no alterations after the different treatment. |
114) ith the control group following the third treatment. |
115) in expression in response to (R)-TEMOSPho treatment. |
116) hese effects of CP can be prevented by HP treatment. |
117) y important evidence on which to base the treatment. |
118) gation was significantly decreased, after treatment. |
119) ral residues can be enhanced by microbial treatment. |
120) ting children with acute malnutrition for treatment. |
121) s there was no significant decrease in GS treatment. |
122) tions targeting cognitive preparation for treatment. |
123) ay be independent of dose and duration of treatment. |
124) nine and thyroxine after 7 and 14 days of treatment. |
125) in the frequency of MN only at day 21 of treatment. |
126) xert the same genotoxic effect at 96 h of treatment. |
127) ne of the promising modalities for cancer treatment. |
128) those who would not benefit from adjuvant treatment. |
129) as adjunctive device to the conventional treatment. |
130) rotein levels in male mice after combined treatment. |
131) need treatment, but 10% require systemic treatment. |
132) ubjected to either TCDD or corticosterone treatment. |
133) ; thus, pain control is a pivotal goal of treatment. |
134) findings with alterations in recommended treatment. |
|